Physician profile
Amatul Basit Khalid
NPI 1205890258
$877.28
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $108 · 2021: $26.55 · 2022: $16.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.96 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $98.91 | 2019 | |
| Lilly USA, LLC | $77.29 | 2019-2021 | |
| Indivior INC. | $53.17 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $48.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.88 | 2019 | |
| Pfizer INC. | $38.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $37.49 | 2019 | |
| Daiichi Sankyo INC. | $29.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.93 | 2019 | |
| Merck Sharp & Dohme LLC | $26.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.18 | 2019 | |
| Glaxosmithkline, LLC. | $25.59 | 2019 | |
| Ucb, INC. | $19.77 | 2020 | |
| Philips North America LLC | $15.95 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2019 | |
| Astellas Pharma US INC | $15.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.26 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amatul Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.